Roche receives CE mark for CGM
By HME News Staff
Updated 12:39 PM CDT, Wed July 10, 2024
BASEL, Switzerland – Roche has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with Type 1 and Type 2 diabetes who are over the age of 18 and who are on flexible insulin therapy. “Maintaining optimal blood glucose levels and preventing adverse glycemic episodes remains a complex task for people living with diabetes, often necessitating up to 180 therapy decisions a day,” said Matt Sause, CEO of Roche Diagnostics. “Our novel CGM solution with its predictive algorithms will help address significant unmet needs associated with diabetes management, empowering users to take control of their condition and live better and healthier lives.” The Accu-Chek SmartGuide CGM sends glucose values measured in real time to the Accu-Chek SmartGuide app. The app then uses those values and other available information to detect glucose patterns and predict future glucose levels. Its integrated AI-enabled predictive algorithms indicate hypoglycemia risk within the next 30 minutes, continuously forecast how glucose levels will develop within the next two hours and estimate the risk of nocturnal hypoglycemia.
Comments